SEC Form 4 · accession 0001209191-16-118596
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Prygocki Sr.
Director
Period of report
May 5, 2016
Accepted (ET)
May 9, 2016 · 7:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $16.63 | May 5, 2016 | A | 8,000 | A | — | May 4, 2026 | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1The shares subject to the stock option shall vest on the one year anniversary of May 5, 2016, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Issuer's Non-Employee Director Compensation Policy.